Fig. 10: Levels of serum CA125 between screening and third follow-up are improved when subjects are treated with high-cell kill ChemoID-predicted therapy. | npj Precision Oncology

Fig. 10: Levels of serum CA125 between screening and third follow-up are improved when subjects are treated with high-cell kill ChemoID-predicted therapy.

From: ChemoID-guided therapy improves objective response rate in recurrent platinum-resistant ovarian cancer randomized clinical trial

Fig. 10

High cell-kill drug cut-offs are above 50% cell kill for the bulk of the tumor and CSCs. Patients randomized in either of the arms were re-grouped into two groups depending on whether they were treated with high-cell kill predicted drugs or not. The CA125 serum levels of subjects treated using high cell kill predicted drugs vs. patients treated with drugs not predicted by the assay were plotted. The slope of the group of patients who were treated with assay-predicted (blue) vs. not-predicted drugs (red) is represented.

Back to article page